The disease burden of AF is greater in Asia-Pacific than other areas of the world. Direct oral
anticoagulants (DOACs) have emerged as effective alternatives to vitamin K antagonists …

Background Whether four direct oral anticoagulants (DOACs) are superior to warfarin
among Asians with non-valvular atrial fibrillation (NVAF) remains unclear in the real-world …

Background Observational studies using large claims databases for diabetes patients have
been increasingly conducted. While validation of outcomes is important in such studies …

Background Although several studies have compared the effectiveness and safety of
rivaroxaban and apixaban in patients with venous thromboembolism (VTE), direct …

We aimed to compare effectiveness and safety of the non‐vitamin K antagonist oral
anticoagulants (NOACs) vs. warfarin for stroke prevention in nonvalvular atrial fibrillation …

The role of non-vitamin K antagonist oral anticoagulants (NOACs) in stroke prevention
remains unclear in Asian patients with atrial fibrillation (AF). Therefore, we performed a meta …

Introduction In randomized trials in atrial fibrillation (AF) patients on direct oral
anticoagulants (DOACs) have a lower risk of bleeding compared with warfarin. However …

BACKGROUND Most of the randomized clinical trials that led to the wide use of non-vitamin
K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation (AF) …

Background: Non-vitamin K antagonist oral anticoagulants (NOACs) are more commonly
used to prevent atrial fibrillation (AF) patients from thromboembolic events than vitamin K …

Background The development of novel oral anticoagulants (NOACs) has changed the
landscape of non-valvular atrial fibrillation (NVAF) management. In this study, the …